{"id":592327,"date":"2022-03-22T12:30:01","date_gmt":"2022-03-22T12:30:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=592327"},"modified":"2022-03-22T12:30:01","modified_gmt":"2022-03-22T12:30:01","slug":"japan-apheresis-market-size-share-and-market-forecast-to-2029-covid19-impact-analysis-datamintelligence","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/japan-apheresis-market-size-share-and-market-forecast-to-2029-covid19-impact-analysis-datamintelligence_592327.html","title":{"rendered":"Japan Apheresis Market Size, Share and Market Forecast to 2029 | COVID-19 Impact Analysis | DataMIntelligence"},"content":{"rendered":"
\n
\"Japan<\/a><\/div>\n
\n
DataM Intelligence<\/div>\n<\/div>\n<\/div>\n
The Japan Apheresis Market is expected to grow at a high CAGR of 6.5% during the forecasting period (2022-2029).<\/div>\n

Market Overview<\/strong><\/p>\n

The Japan apheresis market size was worth $ YY million in 2018 and is estimated to reach $ YY million by 2029, at a CAGR of 6.5% during the forecast period (2021-2029).<\/p>\n

Apheresis is a medical procedure to remove the whole blood from a donor and separate the blood into individual components so that one particular component can be removed. The remaining blood components then are re-introduced back into the bloodstream of the patient or donor.<\/p>\n

 <\/p>\n

Download free sample @ https:\/\/bit.ly\/3qorpP4<\/a><\/em><\/strong><\/p>\n

 <\/p>\n

Market Dynamics <\/strong><\/p>\n

Increasing incidence of hematological disorders<\/p>\n

Rising advancements in technology<\/p>\n

Growing demand for blood plasma in biopharmaceutical companies<\/p>\n

 <\/p>\n

Industry Forces <\/strong><\/p>\n

In Japan, the Adacolumn of JIMRO Co., Ltd. (Gunma, Japan) was approved and reimbursed by the Japan Ministry of Health, Labour and Welfare for the treatment of patients with ulcerative colitis, Crohn’s disease and pustular psoriasis.<\/p>\n

Diseases to which Plasmapheresis can be applied under Health Insurance in Japan include Myasthenia gravis, Guillan-barre syndrome, Chronic inflammatory demyelinating polyneuropathy, Multiple sclerosis, Systemic lupus erythematosus, Malignant rheumatoid arthritis, Macroglobulinemia, Multiple myeloma, Acquired factor VIII positive hemophilia, Severe blood group incompatibility pregnancy, Hemolytic uremic syndrome, Thrombotic<\/p>\n

Thrombocytopenic purpura, Focal segmental glomerular sclerosis, Familial hypercholesterolemia, Arteriosclerosis obliterans, Chronic Hepatitis C, Fulminant hepatitis, Postoperative hepatic failure, acute hepatic failure, Drug intoxication, and Kawasaki disease.<\/p>\n

 <\/p>\n

Market Segmentation<\/strong><\/p>\n